On March 28, 2018 Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small-molecule drugs that address cancer, liver disease and inflammatory diseases, announced today that it will be presenting at the MicroCap Conference, being held on April 9-10 at the Essex House, New York City (Press release, Can-Fite BioPharma, MAR 28, 2018, View Source [SID1234525023]). Can-Fite’s Chief Financial Officer, Motti Farbstein will be delivering the corporate presentation and showcasing the Company’s lead drug candidate, Piclidenoson (CF101), which is in a Phase III trial for rheumatoid arthritis, and Namodenoson (CF102), a liver cancer drug in Phase II trials. Mr. Farbstein will also be hosting a Q&A session with investors and conducting one-on-one meetings.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!